Nova Publishers
My Account Nova Publishers Shopping Cart
HomeBooksSeriesJournalsReference CollectionseBooksInformationSalesImprintsFor Authors
  Top » Catalog » Books » Medicine » Hematologic Disorders » Deep Vein Thrombosis: Symptoms, Diagnosis and Treatments Chapters » My Account  |  Cart Contents  |  Checkout   
Quick Find
Use keywords to find the product you are looking for.
Advanced Search
What's New? more
Central Asia: Perspectives and Present Challenges
Shopping Cart more
0 items
Shipping & Returns
Privacy Notice
Conditions of Use
Contact Us
Notifications more
NotificationsNotify me of updates to Thromboembolic events and cancer (pp. 11-34)
Tell A Friend
Tell someone you know about this product.
Thromboembolic events and cancer (pp. 11-34) $100.00
Authors:  Chapter 2: Thromboembolic events and cancer (Jennifer Foglietta, Stefania Gori, Lucia Stocchi and Lucio Crinò)
A venous thromboembolism is a common complication in patients with cancer, and it is associated with high morbidity, mortality, medical care and costs. Classical clinical symptoms of DVT are: pain, unilateral edema and heaviness in the distal extremity to the site of the venous thrombosis or edema in the face, neck or supraclavicular space. These signs and symptoms are not present in all cases so the diagnosis of DVT and PE made on clinical ground alone is notoriously unreliable. A clinical suspicion for VTE requires sensitive imaging studies such as a color duplex ultrasonography, spiral chest CT and ventilation-perfusion scan; in some cases, CT or MR venography could be useful. VTE risk factors in cancer patients are related to the type and stage of tumors, to the characteristics of patients (age, familial or acquired hypercoagulability,
medical comorbidities, performance status) and to the treatment (surgery, chemotherapy, endocrine therapy, insertion of central venous catheter). Modifiable risk factors are obesity, smoking history and exercise. Currently available drugs for preventing and treatingVTE are vitamin K antagonists (VKA), unfractioned heparin (UFH) and low molecular weight heparins (LMWHs). New antithrombotic agents, such as oral IIa and Xa inhibitors, could be useful, but further studies are needed. 

Available Options:
This Item Is Currently Unavailable.
Special Focus Titles
01.Violent Communication and Bullying in Early Childhood Education
02.Cultural Considerations in Intervention with Women and Children Exposed to Intimate Partner Violence
03.Chronic Disease and Disability: The Pediatric Lung
04.Fruit and Vegetable Consumption and Health: New Research
05.Fire and the Sword: Understanding the Impact and Challenge of Organized Islamism. Volume 2

Nova Science Publishers
© Copyright 2004 - 2021

Thromboembolic events and cancer (pp. 11-34)